Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Disease Incidence
100%
Outcome Prediction
100%
Incidence/prevalence
100%
Immunopathology
100%
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
100%
Myelin Oligodendrocyte Glycoprotein Antibody
88%
Aquaporin-4 IgG
43%
Multiple Sclerosis
35%
Cerebrospinal Fluid
32%
Neuromyelitis Optica Spectrum Disorder (NMOSD)
27%
Patient Care
19%
Prognostic Value
19%
Diagnostic Utility
19%
IgG Titer
16%
Novel Treatments
16%
MRI Lesions
16%
Demyelinating Disease
11%
Clinical Course
8%
Disease Pathogenesis
8%
Clinical Preparedness
8%
Resource Allocation
8%
Risk Factors
8%
Knowledge Gaps
8%
Epidemiology
8%
Clinical Trial Design
8%
World Regions
8%
Clinical Treatment
8%
Disease Epidemiology
8%
Phase II Trial
8%
Care Planning
8%
Biobank
8%
Clinical Prognosis
8%
Living Cells
8%
Epidemiologic
8%
Complement Deposition
8%
Eculizumab
8%
Risk Identification
8%
Complement Inhibitors
8%
High Titer
8%
Population-based Incidence
8%
Pathologic
8%
IgG Assay
8%
Multiple Worlds
8%
Specific Aims
8%
Phase 3 Trial
8%
Sero
8%
Pathological Features
8%
Trial Identification
8%
Immunology and Microbiology
Prevalence
100%
Immunopathology
100%
Myelin Oligodendrocyte Glycoprotein
100%
Aquaporin
48%
Multiple Sclerosis
35%
Cerebrospinal Fluid
32%
Magnetic Resonance Imaging
27%
Neuromyelitis Optica
27%
Titer
24%
Cohort Effect
16%
Epidemiology
16%
Clinically Isolated Syndrome
11%
Intravenous Immunoglobulin
8%
Eculizumab
8%
Complement Inhibitor
8%
Complement Deposition
8%
Biochemistry, Genetics and Molecular Biology
Prevalence
100%
Myelin Oligodendrocyte Glycoprotein
100%
Aquaporin 4
48%
Magnetic Resonance Imaging
27%
Intravenous Immunoglobulin
24%
Titer
24%
Complement Deposition
8%
Clinical Trial Design
8%
Clinical Trial
8%